VJHemOnc is committed to improving our service to you

ASCO 2019 | Myeloma: pomalidomide, bortezomib and dexamethasone

VJHemOnc is committed to improving our service to you

Paul Richardson

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us about the results of a study investigating the use of pomalidomide, bortezomib and dexamethasone for the treatment of multiple myeloma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter